Skip to main
  1. Stocks
  2. Telix Pharmaceuticals Ltd
  3. Forecast
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is supported by a still-healthy core commercial engine, with 3Q26 revenue of $245MM and Precision Medicine revenue of $201MM up 30% y/y, while management reiterated confidence in >25% Precision Medicine growth for FY26 and revenue still tracking toward the upper end of the $950-970MM range. The bullish case is strengthened by a widening catalyst set: Pixclara created its first U.S. commercial presence in neuro-oncology, BiPASS has completed enrollment with FDA support for an NDA pathway, and Zircaix resubmission is planned near-term, all of which broaden growth beyond Illuccix. The proposed $1.65B ITM acquisition is strategically compelling because it adds scaled Lu-177 and Ac-225 supply, a $273MM revenue business in 2025 with >40% manufacturing gross margins, and a potentially profitable therapeutic asset in ITM-11, improving vertical integration and long-term earnings power.

Bears say

Telix Pharmaceuticals is exposed to meaningful downside because its valuation hinges on a concentrated portfolio of clinical-stage programs that could fail in development or face regulatory setbacks. The company also depends heavily on Illuccix for revenue, so any inability to achieve sales estimates would directly weaken its fundamental outlook and pressure growth. With pipeline assets spanning urologic oncology, neuro-oncology, musculoskeletal oncology, and hematology, execution risk remains high, and disappointments in either commercialization or clinical progress could impair results.

TLX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

TLX Analyst Forecast & Price Prediction

Get the latest TLX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 3 analysts, TLX has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


TLX Analyst Forecast & Price Prediction

Get the latest TLX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TLX stock data and trends